Seminars in Oncology
Volume 33 , Pages 23-28 , April 2006

Beyond Detectable Minimal Residual Disease in Chronic Lymphocytic Leukemia

  • Peter Hillmen

      Affiliations

    • Corresponding Author InformationAddress reprint requests to Peter Hillmen, MB ChB, FRCP, FRCPath, PhD, Leeds Teaching Hospital, NHS Trust, Leeds, United Kingdom

References 

  1. Oscier D , Fegan C , Hillmen P , et al.   Guidelines on the diagnosis and management of chronic lymphocytic leukaemia . Br J Haematol . 2004;125:294–317
  2. Keating MJ , O’Brien S , Lerner S , et al.   Long-term follow-up of patients with chronic lymphocytic leukemia (CLL) receiving fludarabine regimens as initial therapy . Blood . 1998;92:1165–1171
  3. Rai KR , Peterson BL , Appelbaum FR , et al.   Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia . N Engl J Med . 2000;343:1750–1757
  4. Dighiero G , Binet J-L . When and how to treat chronic lymphocytic leukemia . N Engl J Med . 2000;343:1799–1801
  5. Dighiero G , Maloum K , Desablens B , et al.   Chlorambucil in indolent chronic lymphocytic leukemia . N Engl J Med . 1998;338:1506–1514
  6. Shanafelt TD , Geyer SM , Kay NE . Prognosis at diagnosis (integrating molecular biologic insights into clinical practice for patients with CLL) . Blood . 2004;103:1202–1210
  7. Rai KR , Sawitsky A , Cronkite EP , et al.   Clinical staging of chronic lymphocytic leukemia . Blood . 1975;46:219–234
  8. Binet JL , Auquier A , Dighiero G , et al.   A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis . Cancer . 1981;48:198–206
  9. Hamblin TJ , Davis Z , Gardiner A , et al.   Unmutated Ig Vh genes are associated with a more aggressive form of chronic lymphocytic leukemia . Blood . 1999;94:1848–1854
  10. Damle RN , Ghiotto F , Valetto A , et al.   B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated antigen-experienced B lymphocytes . Blood . 2002;99:4087–4093
  11. Hamblin T . Is chronic lymphocytic leukemia one disease? . Haematologica . 2002;87:1233–1235
  12. Wiestner A , Rosendwald A , Barry TS , et al.   ZAP-70 expression identified a chronic lymphocytic leukemia subtype with unmutated immunoglobulin genes, inferior clinical outcome and distinct gene expression profile . Blood . 2003;101:4944–4951
  13. Rassenti LZ , Huynh L , Toy TL , et al.   ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia . N Engl J Med . 2004;351:893–901
  14. Crespo M , Bosch F , Villamor N , et al.   ZAP-70 expression as a surrogate for immunoglobulin variable region mutations in chronic lymphocytic leukemia . N Engl J Med . 2003;348:1764–1775
  15. Stilgenbauer S . Chronic lymphocytic leukaemia with high-risk genetics (Disease progression and resistance to therapy) . Leuk Lymphoma . 2005;46(suppl 1):S6
  16. Volkheimer AD , Levesque MC , Beasley BE , et al.   Prognostic features in chronic lymphocytic leukaemia—Lack of utility of Zap-70 as a prognostic marker . Leuk Lymphoma . 2005;46(suppl 1):20; (abstr S44)
  17. Döhner H , Stilgenbauer S , Benner A , et al.   Genomic aberrations and survival in chronic lymphocytic leukemia . N Engl J Med . 2000;343:1910–1916
  18. Sturm I , Bosanquet AG , Hermann S , et al.   Mutation of p53 and consecutive selective drug resistance in B-CLL occurs as a consequence of prior DNA-damaging chemotherapy . Cell Death Differ . 2003;10:477–484
  19. Döhner H , Fischer K , Bentz M , et al.   p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukemias . Blood . 1995;85:1580–1589
  20. Byrd JC , Smith L , Hackbarth ML , et al.   Interphase cytogenetic abnormalities in chronic lymphocytic leukemia may predict response to rituximab . Cancer Res . 2003;63:36–38
  21. el Rouby S , Thomas A , Costin D , et al.   p53 gene mutation in B-cell chronic lymphocytic leukemia is associated with drug resistance and is independent of MDR1/MDR3 gene expression . Blood . 1993;82:3452–3459
  22. Lozanski G , Heerema NA , Flinn IW , et al.   Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions . Blood . 2004;103:3272–3281
  23. Stilgenbauer S , Winkler D , Krober A , et al.   Subcutaneous Campath-1H (alemtuzumab) in fludarabine-refractory CLL (Interim analysis of the CLL2h study of the German CLL Study Group (GCLLSG)) . Blood . 2004;104:235; (abstr 478)
  24. Cheson BD , Bennett JM , Grever M , et al.   National Cancer Institute-sponsored working group guidelines for chronic lymphocytic leukemia (Revised guidelines for diagnosis and treatment) . Blood . 1996;87:4990–4997
  25. Rawstron AC , Kennedy B , Evans PAS , et al.   Quantitation of minimal residual disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy . Blood . 2001;98:29–35
  26. Keating MJ , O’Brien S , Kontoyiannis D , et al.   Results of first salvage therapy for patients refractory to a fludarabine regimen in chronic lymphocytic leukemia . Leuk Lymphoma . 2002;43:1755–1762
  27. Moreton P , Kennedy B , Lucas G , et al.   Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival . J Clin Oncol . 2005;23:2971–2979
  28. Bosch F , Ferrer A , Lopez-Guillermo A , et al.   Fludarabine, cyclophosphamide and mitoxantrone in the treatment of resistant or relapsed chronic lymphocytic leukaemia . Br J Haematol . 2002;119:976–984
  29. Campath Product Insert . Seattle, WA: Berlex, Inc; 2002;
  30. Rituxan Product Insert. San Diego, CA, IDEC Pharmaceutical Corporation and South San Francisco, CA, Genentech Inc, 2004
  31. Montillo M , Tedschi A , Rossi V , et al.   Consolidation with alemtuzumab after a response to fludarabine in patients with CLL (confirmation of the efficacy to purge residual disease) . Leuk Lymphoma . 2005;46(suppl 1):107; (abstr S93)
  32. O’Brien SM , Gribben JG , Thomas DA , et al.   Alemtuzumab for minimal residual disease in CLL . Blood . 2003;102:109a; (abstr 371)
  33. Wendtner C-M , Ritgen M , Schweighofer CD , et al.   Consolidation with alemtuzumab in patients with chronic lymphocytic leukemia (CLL) in first remission—Experience on safety and efficacy within a randomized multicenter phase III trial of the German CLL study group . Leukemia . 2004;18:1093–1101
  34. Keating M , O’Brien S , Albitar M , et al.   Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4079–4088
  35. Wierda W , O’Brien S , Wen S , et al.   Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia . J Clin Oncol . 2005;23:4070–4078
  36. Elter T , Borchmann P , Schulz H , et al.   Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia (Results of a phase II trial) . J Clin Oncol . 2005;23:7024–7031

PII: S0093-7754(06)00058-3

doi: 10.1053/j.seminoncol.2006.01.026

Seminars in Oncology
Volume 33 , Pages 23-28 , April 2006

Article Tools

* Image Usage & Resolution